Erlotinib price

Erlotinib (Erlotinib) is an oral targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC) and some other types of cancer. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which interfere with the growth and spread of tumor cells by inhibiting the activity of specific enzymes.

Erlotinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The domestic price ranges from about 700 to 1,000. The specification is 150mg*7 tablets. Due to different medical insurance policies in different places, the price is also different. Please consult the local pharmacy or medical insurance bureau for details. Erlotinib abroad is mainly an Indian generic drug, with a price of about 900 yuan. The specifications are divided into 100mg*30 tablets and 150mg*30 tablets, which are about four times the domestic specifications, but the price is similar to that in China.

The mechanism of action of erlotinib is related to the epidermal growth factor receptor (EGFR) in tumor cells. EGFR is a membrane receptor tyrosine kinase involved in regulating cell growth, differentiation and survival. In some cancers, EGFR is overactive, causing abnormal proliferation of tumor cells. Erlotinib binds to EGFR and blocks its tyrosine kinase activity, thereby blocking the signaling pathways of cancer cells and slowing down the growth and spread of tumors.

Using erlotinib may cause some adverse reactions, including skin rash, diarrhea, nausea, fatigue, etc. The severity of these reactions varies between individuals, but in most cases they are manageable. During the medication process, the doctor will closely monitor the patient's symptoms and adjust the treatment plan if necessary.

Before taking erlotinib, you should tell your doctor about your allergies, medication history, and existing health problems. Especially for pregnant and lactating women, as well as patients with severe liver function problems, they need to be used under the guidance of a doctor.

In summary, erlotinib is a targeted drug for non-small cell lung cancer and pancreatic cancer that slows down tumor growth and spread by inhibiting signaling pathways within tumor cells. Despite some adverse effects, under a doctor's supervision, it can be an effective treatment option to help patients control the progression of their cancer.